Frederick W Miller

List of Publications by Year in Descending Order

228 papers	12,905 citations	62 h-index	107 g-index
251 ext. papers	15,276 ext. citations	6.7 avg, IF	5.94 L-index

#	Paper	IF	Citations
228	Hygiene Hypothesis Indicators and Prevalence of Antinuclear Antibodies in US Adolescents.. *Frontiers in Immunology*, **2022**, 13, 789379	8.4	0
227	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). *Clinical and Experimental Rheumatology*, **2022**, 40, 214-218	2.2	0
226	The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry.. *Frontiers in Medicine*, **2022**, 9, 842586	4.9	
225	Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes.. *Pediatric Rheumatology*, **2022**, 20, 28	3.5	
224	Defining anti-synthetase syndrome: a systematic literature review.. *Clinical and Experimental Rheumatology*, **2022**, 40, 309-319	2.2	0
223	Idiopathic inflammatory myopathies. *Nature Reviews Disease Primers*, **2021**, 7, 86	51.1	7
222	Slicing and dicing myositis for cures and prevention. *Nature Reviews Rheumatology*, **2021**, 17, 255-256	8.1	
221	Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis. *Clinical Rheumatology*, **2021**, 40, 4095-4100	3.9	0
220	Anti-cortactin autoantibodies are associated with key clinical features in adult myositis but are rarely present in juvenile myositis. *Arthritis and Rheumatology*, **2021**,	9.5	1
219	A Biomedical Knowledge Graph System to Propose Mechanistic Hypotheses for Real-World Environmental Health Observations: Cohort Study and Informatics Application. *JMIR Medical Informatics*, **2021**, 9, e26714	3.6	1
218	Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. *Rheumatology*, **2021**, 60, 1839-1849	3.9	8
217	Response to: Correspondence on EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups by Irfan. *Annals of the Rheumatic Diseases*, **2021**,	2.4	1
216	HLA-DRB1 allelic epitopes that associate with autoimmune disease risk or protection activate reciprocal macrophage polarization. *Scientific Reports*, **2021**, 11, 2599	4.9	1
215	Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. *Clinical and Experimental Rheumatology*, **2021**, 39, 351-356	2.2	1
214	Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. *Annals of the Rheumatic Diseases*, **2020**, 79, 1234-1242	2.4	23
213	Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. *Scientific Reports*, **2020**, 10, 4462	4.9	7
212	Increasing Prevalence of Antinuclear Antibodies in the United States. *Arthritis and Rheumatology*, **2020**, 72, 1026-1035	9.5	50

211	Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. *JCI Insight*, **2020**, 5,	9.9	23
210	Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960-2014. *PLoS ONE*, **2020**, 15, e0226516	3.7	8
209	Introduction to Myositis **2020**, 1-6		
208	Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. *Arthritis Care and Research*, **2020**, 72, 1636-1644	4.7	6
207	Noninfectious Environmental Agents and Autoimmunity **2020**, 345-362		1
206	Transethnic associations among immune-mediated diseases and single-nucleotide polymorphisms of the aryl hydrocarbon response gene ARNT and the PTPN22 immune regulatory gene. *Journal of Autoimmunity*, **2020**, 107, 102363	15.5	5
205	Response to: Comment on: Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis by Sabbagh S by Yang. *Annals of the Rheumatic Diseases*, **2020**, 79, e97	2.4	
204	Long-term outcomes in Juvenile Myositis patients. *Seminars in Arthritis and Rheumatism*, **2020**, 50, 149-155	5.3	9
203	Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. *Journal of Rheumatology*, **2020**, 47, 1011-1018	4.1	10
202	Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. *Arthritis Research and Therapy*, **2020**, 22, 69	5.7	17
201	Identification of distinctive interferon gene signatures in different types of myositis. *Neurology*, **2019**, 93, e1193-e1204	6.5	39
200	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. *Annals of the Rheumatic Diseases*, **2019**, 78, 996-1002	2.4	48
199	Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. *Annals of the Rheumatic Diseases*, **2019**, 78, 988-995	2.4	58
198	Risk factors and disease mechanisms in myositis. *Nature Reviews Rheumatology*, **2018**, 14, 255-268	8.1	62
197	The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. *Seminars in Arthritis and Rheumatism*, **2018**, 48, 504-512	5.3	19
196	Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. *Annals of the Rheumatic Diseases*, **2018**, 77, 714-719	2.4	22
195	Medications received by patients with juvenile dermatomyositis. *Seminars in Arthritis and Rheumatism*, **2018**, 48, 513-522	5.3	12
194	A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. *Seminars in Arthritis and Rheumatism*, **2018**, 47, 858-864	5.3	36

193	Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. *Rheumatology*, **2018**, 57, 1956-1963	3.9	11
192	Prescription medication use and antinuclear antibodies in the United States, 1999-2004. *Journal of Autoimmunity*, **2018**, 92, 93-103	15.5	6
191	Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients. *Arthritis Care and Research*, **2017**, 69, 1088-1094	4.7	49
190	Predictors of Reduced Health-Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies. *Arthritis Care and Research*, **2017**, 69, 1743-1750	4.7	12
189	Environmental factors associated with disease flare in juvenile and adult dermatomyositis. *Rheumatology*, **2017**, 56, 1342-1347	3.9	29
188	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials	9.5	36
187	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology	9.5	33
186	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology	2.4	65
185	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials	2.4	24
184	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. *Annals of the Rheumatic Diseases*, **2017**, 76, 1955-1964	2.4	393
183	Antinuclear antibodies and mortality in the National Health and Nutrition Examination Survey (1999-2004). *PLoS ONE*, **2017**, 12, e0185977	3.7	3
182	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. *RMD Open*, **2017**, 3, e000507	5.9	66
181	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. *Arthritis and Rheumatology*, **2017**, 69, 2271-2282	9.5	210
180	The Association of Arsenic Exposure and Metabolism With Type 1 and Type 2 Diabetes in Youth: The SEARCH Case-Control Study. *Diabetes Care*, **2017**, 40, 46-53	14.6	42
179	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. *Rheumatology*, **2017**, 56, 1884-1893	3.9	23
178	CD3Z hypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3□chain expression in T cells. *Rheumatology*, **2017**, 56, 467-476	3.9	12
177	Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. *Rheumatology*, **2016**, 55, 441-9	3.9	31
176	Juvenile Dermatomyositis **2016**, 351-383.e18		20

175	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. *Annals of the Rheumatic Diseases*, **2016**, 75, 1558-66	2.4	85
174	Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. *Annals of the Rheumatic Diseases*, **2016**, 75, 1599-606	2.4	27
173	Associations Between Selected Xenobiotics and Antinuclear Antibodies in the National Health and Nutrition Examination Survey, 1999-2004. *Environmental Health Perspectives*, **2016**, 124, 426-36	8.4	17
172	Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis. *Arthritis and Rheumatology*, **2016**, 68, 761-8	9.5	34
171	Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. *Rheumatology*, **2016**, 55, 1673-80	3.9	10
170	Diagnosis and classification of idiopathic inflammatory myopathies. *Journal of Internal Medicine*, **2016**, 280, 39-51	10.8	94
169	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. *Genes and Immunity*, **2015**, 16, 470-80	4.4	75
168	Chimeric cells of maternal origin do not appear to be pathogenic in the juvenile idiopathic inflammatory myopathies or muscular dystrophy. *Arthritis Research and Therapy*, **2015**, 17, 238	5.7	5
167	Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases. *PLoS ONE*, **2015**, 10, e0142486	3.7	9
166	Management of inflammatory muscle disease **2015**, 1248-1254		
165	Non-infectious Environmental Agents and Autoimmunity **2014**, 283-295		0
164	A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. *Arthritis and Rheumatology*, **2014**, 66, S70-S71	9.5	12
163	Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. *Arthritis Care and Research*, **2014**, 66, 732-40	4.7	51
162	Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. *Autoimmunity Reviews*, **2014**, 13, 367-71	13.6	183
161	A25: The Association of Immunogenetic and Environmental Factors with Disease Course in Patients with Juvenile Idiopathic Inflammatory Myopathies. *Arthritis and Rheumatology*, **2014**, 66, S39-S40	9.5	1
160	Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. *Arthritis and Rheumatology*, **2014**, 66, 740-9	9.5	167
159	Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis. *BMC Musculoskeletal Disorders*, **2014**, 15, 67	2.8	11
158	Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy. *Nephrology Dialysis Transplantation*, **2014**, 29, 2020-7	4.3	40

157	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax*, **2014**, 69, 428-36	7.3	75
156	A58: Demographics, Clinical Features and Therapies of Patients with Juvenile Dermatomyositis Participating in a National Myositis Patient Registry. *Arthritis and Rheumatology*, **2014**, 66, S86-S87	9.5	3
155	Accommodating measurements below a limit of detection: a novel application of Cox regression. *American Journal of Epidemiology*, **2014**, 179, 1018-24	3.8	34
154	Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. *Current Opinion in Rheumatology*, **2014**, 26, 724-41	5.3	13
153	Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. *International Journal of Molecular Sciences*, **2014**, 15, 14269-97	6.3	70
152	Reproductive and hormonal risk factors for antinuclear antibodies (ANA) in a representative sample of U.S. women. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 2492-502	4	16
151	Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. *Clinical and Experimental Rheumatology*, **2014**, 32, 689-96	2.2	14
150	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. *Arthritis and Rheumatism*, **2013**, 65, 314-24		383
149	Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. *Arthritis and Rheumatism*, **2013**, 65, 3239-47		94
148	The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. *Medicine (United States)*, **2013**, 92, 223-243	1.8	176
147	Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. *Arthritis and Rheumatism*, **2013**, 65, 1934-41		49
146	Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. *Annals of the Rheumatic Diseases*, **2013**, 72, 350-6	2.4	32
145	Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy. *Arthritis Care and Research*, **2013**, 65, 1969-75	4.7	12
144	The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. *Medicine (United States)*, **2013**, 92, 25-41	1.8	111
143	Post-zygotic and inter-individual structural genetic variation in a presumptive enhancer element of the locus between the IL10R and IFNAR1 genes. *PLoS ONE*, **2013**, 8, e67752	3.7	2
142	Criteria for environmentally associated autoimmune diseases. *Journal of Autoimmunity*, **2012**, 39, 253-8	15.5	97
141	Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. *Journal of Autoimmunity*, **2012**, 39, 259-71	15.5	219
140	New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. *Annals of the Rheumatic Diseases*, **2012**, 71 Suppl 2, i82-5	2.4	50

139	Polymyositis and Dermatomyositis **2012**, 1716-1720		2
138	Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. *Arthritis and Rheumatism*, **2012**, 64, 2319-27		241
137	Age-related somatic structural changes in the nuclear genome of human blood cells. *American Journal of Human Genetics*, **2012**, 90, 217-28	11	139
136	Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. *Open Rheumatology Journal*, **2012**, 6, 54-63	0.2	36
135	Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases. *Arthritis Research and Therapy*, **2011**, 13, R181	5.7	10
134	Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. *Arthritis Research and Therapy*, **2011**, 13, R69	5.7	29
133	State of the art: what we know about infectious agents and myositis. *Current Opinion in Rheumatology*, **2011**, 23, 585-94	5.3	27
132	Xenotropic murine leukemia virus-related virus is not associated with chronic fatigue syndrome in patients from different areas of the us in the 1990s. *Virology Journal*, **2011**, 8, 450	6.1	5
131	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity	4.7	203
130	Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. *Arthritis and Rheumatism*, **2011**, 63, 3633-9 Quantitative Muscle T. *Arthritis Care and Research*, **2011**, 63 Suppl 11, S118-57		48
129	Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromes. *Journal of Proteome Research*, **2011**, 10, 2969-78	5.6	30
128	Environmental agents and autoimmune diseases. *Advances in Experimental Medicine and Biology*, **2011**, 711, 61-81	3.6	30
127	Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. *JAMA - Journal of the American Medical Association*, **2011**, 305, 183-90	27.4	94
126	Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. *Rheumatology*, **2010**, 49, 2381-90	3.9	34
125	Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. *Journal of Immunology*, **2010**, 184, 4497-509	5.3	79
124	Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. *Genome Research*, **2010**, 20, 170-9	9.7	486
123	Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. *Arthritis Care and Research*, **2010**, 62, 465-72	4.7	154
122	Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface?. *Arthritis and Rheumatism*, **2010**, 62, 2619-22		2

121	Metabolic abnormalities and cardiovascular risk factors in children with myositis. *Journal of Pediatrics*, **2009**, 155, 882-7	3.6	18
120	HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. *Arthritis and Rheumatism*, **2009**, 60, 1179-86		32
119	Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms. *Arthritis and Rheumatism*, **2009**, 61, 1305-11		15
118	Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. *Arthritis and Rheumatism*, **2009**, 60, 2499-504		99
117	Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. *Arthritis and Rheumatism*, **2009**, 60, 3425-35		83
116	Genetic risk and protective factors for the idiopathic inflammatory myopathies. *Current Rheumatology Reports*, **2009**, 11, 287-94	4.9	16
115	Inflammatory Myopathies **2009**, 191-199		
114	Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. *Arthritis Research and Therapy*, **2009**, 11, R159	5.7	29
113	On Determining the Effects of Therapy on Disease Damage in Non- randomized Studies with Multiple Treatments: A study of Juvenile Myositis. *Communications in Statistics - Theory and Methods*, **2009**, 38, 3268-3281	0.5	
112	Classification of Idiopathic Inflammatory Myopathies **2009**, 15-28		4
111	Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. *Dermatology Online Journal*, **2009**, 15, 1	1	11
110	Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. *Dermatology Online Journal*, **2009**, 15, 2	1	9
109	UV radiation regulates Mi-2 through protein translation and stability. *Journal of Biological Chemistry*, **2008**, 283, 34976-82	5.4	43
108	Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. *Medicine (United States)*, **2008**, 87, 70-86	1.8	113
107	Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. *Arthritis and Rheumatism*, **2008**, 59, 352-6		33
106	Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. *Arthritis and Rheumatism*, **2008**, 59, 214-21		44
105	Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. *Arthritis and Rheumatism*, **2008**, 58, 3239-46		37
104	Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: comment on the article by Ruperto et al. *Arthritis and Rheumatism* , **2008**, 59, 1197-8; author reply 1198-9		2

103	Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. *Arthritis and Rheumatism*, **2008**, 58, 3941-50		68
102	Idiopathic Inflammatory Myopathies **2008**, 368-374		
101	Mechanisms of disease: Environmental factors in the pathogenesis of rheumatic disease. *Nature Clinical Practice Rheumatology*, **2007**, 3, 172-80		65
100	Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. *Arthritis and Rheumatism*, **2007**, 56, 2719-28		43
99	Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. *Arthritis and Rheumatism*, **2007**, 57, 881-4		48
98	Developing international consensus on measures of improvement for patients with myositis. *Statistical Methods in Medical Research*, **2007**, 16, 51-64	2.3	5
97	Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case-control study. *Arthritis Research and Therapy*, **2007**, 9, R95	5.7	5
96	A novel autoantibody to a 155-kd protein is associated with dermatomyositis. *Arthritis and Rheumatism*, **2006**, 54, 3682-9		340
95	HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. *Arthritis and Rheumatism*, **2006**, 54, 3670-81		59
94	Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. *Arthritis and Rheumatism*, **2006**, 54, 3979-87		59
93	Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. *Medicine (United States)*, **2006**, 85, 111-127	1.8	118
92	Is occupational exposure to mineral oil a risk factor for rheumatoid arthritis?. *Nature Clinical Practice Rheumatology*, **2006**, 2, 130-1		0
91	Virus-mediated autoimmunity in Multiple Sclerosis. *Journal of Autoimmune Diseases*, **2006**, 3, 1		27
90	Endothelial cell activation and neovascularization are prominent in dermatomyositis. *Journal of Autoimmune Diseases*, **2006**, 3, 2		62
89	Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. *Arthritis Research and Therapy*, **2006**, 8, R39	5.7	39
88	Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. *Biology of Blood and Marrow Transplantation*, **2006**, 12, 252-66	4.7	344
87	Noninfectious Environmental Agents and Autoimmunity **2006**, 297-307		3
86	Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. *Medicine (United States)*, **2005**, 84, 338-349	1.8	76

85	Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. *Arthritis and Rheumatism*, **2005**, 52, 2433-8		47
84	International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. *Arthritis and Rheumatism*, **2005**, 52, 2607-15		121
83	Clinical Presentation and Therapy of Idiopathic Inflammatory Myopathies. *Journal of Musculoskeletal Pain*, **2004**, 12, 85-91		0
82	Possible roles and determinants of microchimerism in autoimmune and other disorders. *Autoimmunity Reviews*, **2004**, 3, 454-63	13.6	37
81	Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. *Arthritis and Rheumatism*, **2004** , 50, 1595-603		151
80	International consensus on preliminary definitions of improvement in adult and juvenile myositis. *Arthritis and Rheumatism*, **2004**, 50, 2281-90		173
79	Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. *Arthritis and Rheumatism*, **2004**, 51, 365-70		34
78	Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. *Arthritis and Rheumatism*, **2004**, 50, 3646-50		23
77	Autoantibodies as predictive and diagnostic markers of idiopathic inflammatory myopathies. *Autoimmunity*, **2004**, 37, 291-4	3	13
76	Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. *Arthritis and Rheumatism*, **2003**, 48, 2285-93		135
75	HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. *Arthritis and Rheumatism*, **2003**, 48, 2567-72		29
74	Diagnostic criteria for polymyositis and dermatomyositis. *Lancet, The*, **2003**, 362, 1762-3; author reply 1763	40	51
73	Defining Clinical Improvement in Adult and Juvenile Myositis. *Journal of Rheumatology*, **2003**, 30, 603-17	4.1	108
72	Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. *Arthritis and Rheumatism*, **2002**, 46, 1885-93		79
71	Genomic organization, transcriptional mapping, and evolutionary implications of the human bi-directional histidyl-tRNA synthetase locus (HARS/HARSL). *Biochemical and Biophysical Research Communications*, **2002**, 294, 609-14	3.4	10
70	Occupational exposures and autoimmune diseases. *International Immunopharmacology*, **2002**, 2, 303-13	5.8	123
69	Idiopathic inflammatory myopathies. *Rheumatic Disease Clinics of North America*, **2002**, 28, xi-xiii	2.4	2
68	Approaches to risk assessment of immunotoxic effects of chemicals?. *Toxicology*, **2001**, 161, 213-228	4.4	6

67	Update on the genetics of the idiopathic inflammatory myopathies. *Current Opinion in Rheumatology*, **2000**, 12, 482-91	5.3	70
66	Approaches for identifying and defining environmentally associated rheumatic disorders. *Arthritis and Rheumatism*, **2000**, 43, 243-9		76
65	Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. *Arthritis and Rheumatism*, **2000**, 43, 1866-73		111
64	Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. *Clinical and Experimental Immunology*, **2000**, 121, 47-52	6.2	61
63	Idiopathic inflammatory muscle disease: clinical aspects. *Best Practice and Research in Clinical Rheumatology*, **2000**, 14, 37-54	5.3	30
62	Familial autoimmunity and the idiopathic inflammatory myopathies. *Current Rheumatology Reports*, **2000**, 2, 201-11	4.9	29
61	Restricted and shared patterns of TCR beta-chain gene expression in silicone breast implant capsules and remote sites of tissue inflammation. *Journal of Autoimmunity*, **2000**, 14, 283-93	15.5	3
60	Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. *Lancet, The*, **2000**, 356, 2155-6	40	150
59	Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. *Arthritis and Rheumatism*, **1999**, 42, 1285-90		54
58	Novel gastrointestinal tract manifestations in juvenile dermatomyositis. *Journal of Pediatrics*, **1999**, 135, 371-4	3.6	36
57	The Role of Genetic Factors in Autoimmune Disease: Implications for Environmental Research. *Environmental Health Perspectives*, **1999**, 107, 693	8.4	21
56	Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. *Arthritis and Rheumatism*, **1998**, 41, 392-9		144
55	Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. *Arthritis and Rheumatism*, **1998**, 41, 400-5		75
54	Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. *Arthritis and Rheumatism*, **1998**, 41, 710-9		55
53	Classification criteria for the idiopathic inflammatory myopathies. *Current Opinion in Rheumatology*, **1997**, 9, 527-35	5.3	183
52	Classification and treatment of the juvenile idiopathic inflammatory myopathies. *Rheumatic Disease Clinics of North America*, **1997**, 23, 619-55	2.4	106
51	Clinical, serologic, and immunogenetic features in polish patients with idiopathic inflammatory myopathies. *Arthritis and Rheumatism*, **1997**, 40, 1257-1266		2
50	Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. *Arthritis and Rheumatism*, **1997**, 40, 1976-83		113

49	Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. *Arthritis and Rheumatism*, **1997**, 40, 1257-66		120
48	Focal myositis presenting as pseudothrombophlebitis of the neck in a patient with mixed connective tissue disease. *Arthritis and Rheumatism*, **1996**, 39, 1254-8		10
47	Signal Recognition Particle Autoantibodies **1996**, 735-740		
46	Genetics of autoimmune diseases. *Experimental and Clinical Immunogenetics*, **1995**, 12, 182-90		9
45	T cell-mediated immune mechanisms in myositis. *Current Opinion in Rheumatology*, **1995**, 7, 503-9	5.3	10
44	NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. *Annals of Internal Medicine*, **1995**, 122, 715-24	8	102
43	A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. *Arthritis and Rheumatism*, **1994**, 37, 1534-8		82
42	Chronic beryllium disease--from the workplace to cellular immunology, molecular immunogenetics, and back. *Clinical Immunology and Immunopathology*, **1994**, 71, 123-9		47
41	The alpha beta T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. *Journal of Autoimmunity*, **1994**, 7, 321-33	15.5	35
40	New perspectives on the idiopathic inflammatory myopathies of childhood. *Current Opinion in Rheumatology*, **1994**, 6, 575-82	5.3	7
39	CLASSIFICATION AND PROGNOSIS OF INFLAMMATORY MUSCLE DISEASE. *Rheumatic Disease Clinics of North America*, **1994**, 20, 811-826	2.4	20
38	Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. *American Journal of Medicine*, **1993**, 94, 379-87	2.4	236
37	Myositis-Specific Autoantibodies. *JAMA - Journal of the American Medical Association*, **1993**, 270, 1846	27.4	58
36	The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. *Medicine (United States)*, **1993**, 72, 225-35	1.8	69
35	Noninfectious environmental agents associated with myopathies. *Current Opinion in Rheumatology*, **1993**, 5, 712-8	5.3	27
34	Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. *New England Journal of Medicine*, **1992**, 326, 1380-4	59.2	264
33	Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. *Lancet, The*, **1992**, 339, 1192-5	40	125
32	Simultaneous onset of systemic sclerosis (scleroderma) and lung cancer: a case report and histologic analysis of fibrogenic peptides. *American Journal of Medicine*, **1992**, 92, 705-8	2.4	9

31	Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. *Arthritis and Rheumatism*, **1992**, 35, 821-30		80
30	Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. *Arthritis and Rheumatism*, **1991**, 34, 1391-6		76
29	The neuromuscular pathology of the Eosinophilia-Myalgia syndrome. *Journal of Neuropathology and Experimental Neurology*, **1991**, 50, 49-62	3.1	23
28	Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies. *Current Opinion in Rheumatology*, **1991**, 3, 902-10	5.3	20
27	Thyroid stimulating and thyrotrophin binding-inhibitory immunoglobulin activity in patients with systemic lupus erythematosus having thyroid function abnormalities. *Thyroid*, **1991**, 1, 229-34	6.2	9
26	A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. *Medicine (United States)*, **1991**, 70, 360-74	1.8	701
25	Antibody to signal recognition particle in polymyositis. *Arthritis and Rheumatism*, **1990**, 33, 1361-70		226
24	Polymyositis/dermatomyositis associated with dermatitis herpetiformis. *Arthritis and Rheumatism*, **1989**, 32, 1179-81		13
23	Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. *Annals of Internal Medicine*, **1989**, 111, 143-57	8	229
22	Stimulation and partial stabilization of human histidyl-tRNA synthetase by hemoglobin. *FEBS Letters*, **1988**, 229, 203-5	3.8	3
21	An efficient method for enrichment of histidyl-tRNA synthetase (Jo-1 antigen) from HeLa cells. *Journal of Immunological Methods*, **1987**, 98, 235-41	2.5	7
20	An enzyme-linked immunosorbent assay for the detection and quantitation of anti-Jo-1 antibody in human serum. *Journal of Immunological Methods*, **1987**, 98, 243-8	2.5	32
19	Viral and host genetic factors influence encephalomyocarditis virus-induced polymyositis in adult mice. *Arthritis and Rheumatism*, **1987**, 30, 549-56		31
18	Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. *Arthritis and Rheumatism*, **1987**, 30, 1124-31		88
17	Induction of bone xenografts of rabbit growth plate chondrocytes in the nude mouse. *Calcified Tissue International*, **1985**, 37, 250-6	3.9	15
16	Evidence for major differences in ribosomal subunit proteins from Plasmodium berghei and rat liver. *Molecular and Biochemical Parasitology*, **1984**, 12, 249-60	1.9	1
15	Disaccharidase values in iron-deficient infants. *Journal of Pediatrics*, **1981**, 99, 605-8	3.6	12
14	A mucoprotein with colon-specific determinants. *Tissue Antigens*, **1978**, 11, 362-71		14

13	The immunopathophysiological effects of chronic serum sickness on rat choroid plexus, ciliary process and renal glomeruli. *Journal of Neuropathology and Experimental Neurology*, **1977**, 36, 726-33	3.1	29
12	Serum-Derived Immunosuppressive Substances. *International Archives of Allergy and Immunology*, **1977**, 55, 239-246	3.7	2
11	Failure of cobra venom factor to inhibit antigen-induced arthritis. *Arthritis and Rheumatism*, **1977**, 20, 1567		3
10	Application of immunologic probes for contractile proteins to tissue sections. *Clinical Immunology and Immunopathology*, **1976**, 5, 416-28		12
9	Serum-derived immunosuppressive substances. I. Partial purification and range of action. *Transplantation*, **1976**, 21, 179-87	1.8	25
8	Chemical and immunological differences between normal and tumoral colonic mucoprotein antigen. *Nature*, **1975**, 255, 85-7	50.4	34
7	The effect of specific glycosidase treatment on the responsiveness of lymphocytes. I. Response of human lymphocytes to concanavalin-A. *Cellular Immunology*, **1974**, 10, 136-44	4.4	2
6	Characterization of human colonic mucoprotein antigen. *Immunochemistry*, **1974**, 11, 369-75		43
5	Preliminary evidence for the structure of the concanavalin-A binding site on human lymphocytes that induces mitogenesis. *Cellular Immunology*, **1973**, 6, 132-9	4.4	19
4	Glycopeptides of human immunoglobulins□I. *Immunochemistry*, **1972**, 9, 217-228		25
3	Glycopeptides of human immunoglobulins. II. Contribution to the antigenicity of the heavy chain. *Immunochemistry*, **1971**, 8, 99-111		7
2	Glycopeptides of human immunoglobulins. I. Preparation and carbohydrate composition. *Immunochemistry*, **1970**, 7, 423-36		12
1	Vasculitis in the Idiopathic Inflammatory Myopathies433-440		0